Waxman/Hatch Reform Should Clarify Rules, Not Change System - Merck
Executive Summary
Reforms to the Waxman/Hatch patent extension program should focus on "clarification" of patent life, rather than "fundamental changes" to the generic drug approval and extension process, Merck Senior Director-Government Relations Ian Spatz told the National Institute for Health Care Management Sept. 25 in Washington, D.C.
You may also be interested in...
Patent Disputes Do Not Pay Off, Merck Says: Sweet Spot In “Bitter Medicine”
Aggressive patent defensive strategies do not pay off on Wall Street, Merck CEO Ray Gilmartin told Peter Jennings during an ABC News special, "Bitter Medicine: Pills, Profit and the Public Health," which aired May 29
Patent Disputes Do Not Pay Off, Merck Says: Sweet Spot In “Bitter Medicine”
Aggressive patent defensive strategies do not pay off on Wall Street, Merck CEO Ray Gilmartin told Peter Jennings during an ABC News special, "Bitter Medicine: Pills, Profit and the Public Health," which aired May 29
GSK Paxil, AstraZeneca Prilosec Have New "Product By Process" Patents
GlaxoSmithKline's most recent Paxil patent illustrates the latest wrinkle in patent infringement defense: "product by process" patents, attorney Robert Green (Leydig, Voit & Mayer, Chicago) told the National Association of Pharmaceutical Manufacturers bulk workshop March 20 in New York City.